Sunesis Pharmaceuticals Inc. (Nasdaq: SNSS) will present results from a Phase
3 VALOR trial of vosaroxin and cytarabine in patients with relapsed or
refractory acute myeloid leukemia at the 56th American Society of
Hematology Annual Meeting on December 6-9, 2014. The stock price leaped 79 cents to $2.46.
Sunesis to present vosaroxin and cytarabine data
November 17, 2014 at 04:57 AM EST
